EROL, C. Et Al. 2022. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.18, no.9 , 347-353.

EROL, C., ŞENDUR, M. A. N., Bilgetekin, I., BAYIR GARBİOĞLU, D., HAMDARD, J., Akbas, S., ... Hizal, M.(2022). Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.18, no.9, 347-353.

EROL, CİHAN Et Al. "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group," JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.18, no.9, 347-353, 2022

EROL, CİHAN Et Al. "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group." JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.18, no.9, pp.347-353, 2022

EROL, C. Et Al. (2022) . "Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group." JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.18, no.9, pp.347-353.

@article{article, author={CİHAN EROL Et Al. }, title={Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group}, journal={JOURNAL OF CANCER RESEARCH AND THERAPEUTICS}, year=2022, pages={347-353} }